2019
Quality control and quantification in IG/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGS
KNECHT, H.; Tomáš REIGL; M. KOTROVA; F. APPELT; P. STEWART et. al.Základní údaje
Originální název
Quality control and quantification in IG/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGS
Autoři
KNECHT, H.; Tomáš REIGL; M. KOTROVA; F. APPELT; P. STEWART; Vojtěch BYSTRÝ; Adam KREJČÍ; A. GRIONI; Karol PÁL; Kamila STRÁNSKÁ; Karla PLEVOVÁ; J. RIJNTJES; S. SONGIA; M. SVATON; E. FRONKOVA; J. BARTRAM; B. SCHEIJEN; D. HERRMANN; R. GARCIA-SANZ; J. HANCOCK; J. MOPPETT; J.J.M. VAN DONGEN; G. CAZZANIGA; F. DAVI; P.J.T.A. GROENEN; M. HUMMEL; E.A. MACINTYRE; K. STAMATOPOULOS; J. TRKA; A.W. LANGERAK; D. GONZALEZ; C. POTT; M. BRUGGEMANN a Nikos DARZENTAS
Vydání
Leukemia, London, Nature Publishing Group, 2019, 0887-6924
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30204 Oncology
Stát vydavatele
Velká Británie a Severní Irsko
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 8.665
Kód RIV
RIV/00216224:14740/19:00108523
Organizační jednotka
Středoevropský technologický institut
UT WoS
000484399300010
EID Scopus
2-s2.0-85067866924
Klíčová slova anglicky
MINIMAL RESIDUAL DISEASE; ACUTE LYMPHOBLASTIC-LEUKEMIA; CELL LYMPHOMA; IMMUNOGLOBULIN; PCR; STANDARDIZATION; PRIMERS; RELAPSE; RISK
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 24. 10. 2024 16:33, Ing. Marie Švancarová
Anotace
V originále
Assessment of clonality, marker identification and measurement of minimal residual disease (MRD) of immunoglobulin (IG) and T cell receptor (TR) gene rearrangements in lymphoid neoplasms using next-generation sequencing (NGS) is currently under intensive development for use in clinical diagnostics. So far, however, there is a lack of suitable quality control (QC) options with regard to standardisation and quality metrics to ensure robust clinical application of such approaches. The EuroClonality-NGS Working Group has therefore established two types of QCs to accompany the NGS-based IG/TR assays. First, a central polytarget QC (cPT-QC) is used to monitor the primer performance of each of the EuroClonality multiplex NGS assays; second, a standardised human cell line-based DNA control is spiked into each patient DNA sample to work as a central in-tube QC and calibrator for MRD quantification (cIT-QC). Having integrated those two reference standards in the ARResT/Interrogate bioinformatic platform, EuroClonality-NGS provides a complete protocol for standardised IG/TR gene rearrangement analysis by NGS with high reproducibility, accuracy and precision for valid marker identification and quantification in diagnostics of lymphoid malignancies.
Návaznosti
| LM2015085, projekt VaV |
| ||
| NV16-34272A, projekt VaV |
| ||
| 90091, velká výzkumná infrastruktura |
|